Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galychpharm PJSC (UKEX:GFARM) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Galychpharm PJSC Earnings per Share (Diluted) Related Terms
Galychpharm PJSC Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Galychpharm PJSC's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galychpharm PJSC Earnings per Share (Diluted) Chart
Galychpharm PJSC Annual Data
Trend
Earnings per Share (Diluted)
Galychpharm PJSC Semi-Annual Data
Earnings per Share (Diluted)
UKEX:GFARM vs HSTC, STLT, NTRR: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galychpharm PJSC's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galychpharm PJSC PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galychpharm PJSC's PE Ratio distribution charts can be found below:
* The bar in red indicates where Galychpharm PJSC's PE Ratio falls into.
Galychpharm PJSC Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Galychpharm PJSC's Earnings Per Share (Diluted) for the fiscal year that ended in . 20 is calculated as
What does a Earnings per Share (Diluted) of ₴ mean?
Galychpharm PJSC (UKEX:GFARM) has a Earnings per Share (Diluted) of ₴ as of . 20. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Galychpharm PJSC and its competitors.
Is Galychpharm PJSC's Earnings per Share (Diluted) too high?
Galychpharm PJSC's current Earnings per Share (Diluted) is ₴. Overall, Galychpharm PJSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galychpharm PJSC's Earnings per Share (Diluted) compare to HSTC and STLT?
Galychpharm PJSC's Earnings per Share (Diluted) of ₴ can be compared against companies in the Drug Manufacturers industry. The industry median Earnings per Share (Diluted) is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Galychpharm PJSC and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galychpharm PJSC's current Earnings per Share (Diluted) is ₴. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galychpharm PJSC stock overvalued right now?
Galychpharm PJSC (UKEX:GFARM) has a current Earnings per Share (Diluted) of ₴. The current Earnings per Share (Diluted) is ₴. Galychpharm PJSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Galychpharm PJSC (UKEX:GFARM), the current Earnings per Share (Diluted) is ₴ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galychpharm PJSC is engaged in the production and sale of drugs and other medicines. It offers phytochemical substances, crude drugs, injection ampoules, tablets, solutions, extracts, and syrups.
14GF Score
Get the complete analysis for UKEX:GFARM
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UKEX:GFARM has been successfully added to your 
